# EDGAR Filing Document

**Accession Number:** 0001410677
**File Stem:** 0001104659-26-014441
**Filing Date:** 2026-2
**Character Count:** 10036
**Document Hash:** 6fe913085d5ef964f95bc04058b2a99f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-014441.hdr.sgml**: 20260212

**ACCESSION NUMBER**: 0001104659-26-014441

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260212

**FILED AS OF DATE**: 20260212

**DATE AS OF CHANGE**: 20260212

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Divis Gregory J
- **CENTRAL INDEX KEY:** 0001410677

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37977
- **FILM NUMBER:** 26627800

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10-1 BLANCHARDSTOWN CORPORATE PARK
- **STREET 2:** BALLYCOOLIN
- **CITY:** DUBLIN
- **PROVINCE COUNTRY:** L2

**FORMER NAME:**
- **FORMER CONFORMED NAME:** DIVIS GREG J
- **DATE OF NAME CHANGE:** 20070824
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVADEL PHARMACEUTICALS PLC
- **CENTRAL INDEX KEY:** 0001012477
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10 EARLSFORT TERRACE
- **CITY:** DUBLIN 2
- **PROVINCE COUNTRY:** L2
- **ZIP:** D02 T380
- **BUSINESS PHONE:** 636-449-1830

**MAIL ADDRESS:**
- **STREET 1:** 16640 CHESTERFIELD GROVE ROAD
- **STREET 2:** SUITE 200
- **CITY:** CHESTERFIELD
- **STATE:** MO
- **ZIP:** 63005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLAMEL TECHNOLOGIES SA
- **DATE OF NAME CHANGE:** 19960422

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Divis Gregory J<br><sub>(Last) (First) (Middle)</sub><br>C/O AVADEL PHARMACEUTICALS PLC<br>10 EARLSFORT TERRACE<br><sub>(Street)</sub><br>DUBLIN 2, L2 D02 T380<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>AVADEL PHARMACEUTICALS PLC [ AVDL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2026-02-12 |  | D<sup>(1)(2)</sup> |  | 211105<sup>(3)</sup> | D | 21.00<sup>(1)(2)</sup> | 0 | D |  |
| Ordinary Shares | 2026-02-12 |  | D<sup>(1)(2)</sup> |  | 10000 | D | 21.00<sup>(1)(2)</sup> | 0 | I | By Trust<sup>(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $10.40 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 150000 | <sup>(5)</sup> | 2026-12-14 | Ordinary Shares | 150000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $8.95 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 100000 | <sup>(5)</sup> | 2027-12-12 | Ordinary Shares | 100000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $7.06 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 50000 | <sup>(5)</sup> | 2028-03-22 | Ordinary Shares | 50000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $1.85 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 100000 | <sup>(5)</sup> | 2029-03-07 | Ordinary Shares | 100000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $1.71 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 400000 | <sup>(5)</sup> | 2029-05-30 | Ordinary Shares | 400000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $6.79 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 500000 | <sup>(5)</sup> | 2030-12-08 | Ordinary Shares | 500000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $8.20 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 310000 | <sup>(5)</sup> | 2031-12-07 | Ordinary Shares | 310000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $4.69 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 350000 | <sup>(5)</sup> | 2032-08-04 | Ordinary Shares | 350000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $13.57 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 600000 | <sup>(5)</sup> | 2034-02-20 | Ordinary Shares | 600000 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $7.87 | 2026-02-12 |  | D<sup>(5)</sup> |  |  | 310000 | <sup>(5)</sup> | 2030-03-06 | Ordinary Shares | 310000 | <sup>(5)</sup> | 0 | D |  |

---

### Footnotes:

(1) Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.

(2) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").

(3) Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.

(4) These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary.

(5) Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

**Signature:** /s/ Robert E. Puopolo, as Attorney-in-Fact  
**Date:** 2026-02-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**